Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs
摘要:
A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5-methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H- pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects. (C) 2014 Elsevier Ltd. All rights reserved.
The present invention relates to compounds of the general formula (I):
wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1):
R
1
means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others.
The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.
The present invention relates to compounds of the general formula (I):
wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1):
R1 means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others.
The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.
The present invention relates to compounds of the general formula (I):
wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1):
R1 means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others.
The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.
本发明涉及通式 (I) 的化合物:
其中 A、B、C 和 D 各自独立地为一个甲基或一个氮原子,所述甲基可选择具有一个或多个取代基,其中至少一个取代基指甲基;E 指由下式(E1)代表的基团:
R1 指一个低级烷基或一个芳基,可选择具有一个或多个取代基;或指一个低级亚烷基,与 E 的任意可连接位置相连;等等。
本发明的化合物可作为治疗与 NPY 有关的各种疾病的药物。